The standard dose of Imatinib is 400 mg/day, and it was established based on two randomized phase III trials, in patients with c-kit positive metastatic or unresectable GIST, comparing daily doses of 400 vs 800 mg [19, 20]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.